Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072801
Filing Date
2025-05-15
Accepted
2025-05-15 16:52:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9013
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 74817
  Complete submission text file 0000950170-25-072801.txt   113739
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Subject) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94897 | Film No.: 25954905
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SCILEX HOLDING COMPANY 960 SAN ANTONIO ROAD PALO ALTO CA 94303
Business Address
Lee Tien-Li (Filed by) CIK: 0001940120 (see all company filings)

Type: SCHEDULE 13G